vTv Therapeutics (NASDAQ:VTVT) Issues Quarterly Earnings Results

vTv Therapeutics (NASDAQ:VTVT) released its earnings results on Tuesday. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.09) by $0.51, FiscalAI reports. The firm had revenue of ($0.02) million during the quarter.

vTv Therapeutics Stock Performance

vTv Therapeutics stock traded down $0.69 during midday trading on Wednesday, hitting $34.33. 83,779 shares of the company were exchanged, compared to its average volume of 33,746. vTv Therapeutics has a fifty-two week low of $14.00 and a fifty-two week high of $44.00. The firm has a market capitalization of $135.26 million, a PE ratio of -10.37 and a beta of 0.44. The business has a fifty day simple moving average of $36.28 and a two-hundred day simple moving average of $29.22.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on VTVT. BTIG Research reissued a “buy” rating and issued a $49.00 price target (up from $40.00) on shares of vTv Therapeutics in a research report on Tuesday, January 27th. Wall Street Zen upgraded vTv Therapeutics to a “sell” rating in a research note on Saturday, December 27th. Roth Mkm began coverage on shares of vTv Therapeutics in a report on Thursday, January 22nd. They issued a “buy” rating and a $58.00 target price for the company. TD Cowen assumed coverage on shares of vTv Therapeutics in a research report on Monday, January 5th. They set a “buy” rating for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of vTv Therapeutics in a report on Monday, December 29th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $55.25.

Hedge Funds Weigh In On vTv Therapeutics

Large investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. purchased a new stake in vTv Therapeutics in the 4th quarter worth $221,000. Geode Capital Management LLC lifted its holdings in vTv Therapeutics by 84.3% during the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after purchasing an additional 12,896 shares in the last quarter. 683 Capital Management LLC acquired a new stake in shares of vTv Therapeutics in the fourth quarter valued at about $731,000. Finally, Baker BROS. Advisors LP increased its stake in shares of vTv Therapeutics by 52.4% during the third quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock worth $3,463,000 after purchasing an additional 51,000 shares in the last quarter. Institutional investors and hedge funds own 17.51% of the company’s stock.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.